ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
ACDC Metals Ltd
0.060
-0.009
-13.04%
成交量:
12.97万
成交额:
7,916.00
市值:
449.58万
市盈率:
-6.36
高:
0.065
开:
0.065
低:
0.060
收:
0.069
52周最高:
0.160
52周最低:
0.036
股本:
7,493.08万
流通股本:
4,028.75万
量比:
4.88
换手率:
0.32%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.009
每股收益(LYR):
-0.009
净资产收益率:
-6.71%
总资产收益率:
-2.92%
市净率:
0.44
市盈率(LYR):
-6.36
数据加载中...
总览
公司
新闻资讯
公告
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
prnewswire
·
10/18
先声药业(02096.HK):SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书
智通财经
·
09/08
招银国际:首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元
智通财经
·
09/04
阿斯利康第二款ADC药物在国内获批用于乳腺癌
格隆汇
·
08/22
阿斯利康宣布注射用德达博妥单抗(达卓优)正式在国内获批用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不
智通财经
·
08/22
研报掘金|中金:上调药明合联目标价至75港元 中期业绩胜预期且订单增长强劲
格隆汇
·
08/20
德琪医药-B(06996.HK):ATG-022就治疗胃癌/胃食管结合部腺癌获授予突破性治疗药物认定
智通财经
·
08/19
康宁杰瑞JSKN022新药临床试验申请获CDE受理
格隆汇
·
08/03
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ADC.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.06,"timestamp":1764911520000,"preClose":0.069,"halted":0,"volume":129731,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"未开盘","change":-0.009,"latestTime":"12-05 16:12:00 AEDT","open":0.065,"high":0.065,"low":0.06,"amount":7916,"amplitude":0.072464,"askPrice":0.065,"askSize":24612,"bidPrice":0.06,"bidSize":26616,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1765148400000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.069,"openAndCloseTimeList":[[1764889200000,1764910800000]],"volumeRatio":4.878168909376725,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":4.878168909376725,"shares":74930755,"dividePrice":0,"high":0.065,"amplitude":0.072464,"preClose":0.069,"low":0.06,"week52Low":0.036,"pbRate":"0.44","psRate":"13.05","week52High":0.16,"institutionHeld":0,"latestPrice":0.06,"committee":0.039119,"eps":-0.00943,"divideRate":0,"volume":129731,"delay":0,"ttmEps":-0.00943,"open":0.065,"prevYearClose":0.055,"prevWeekClose":0.06,"prevMonthClose":0.068,"prevQuarterClose":0.065,"fiveDayClose":0.068,"twentyDayClose":0.066,"sixtyDayClose":0.066},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that at the 2025 European Society for Medical Oncology Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative breast cancer was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration and was included in the priority review and approval process.","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4203","BC","HR","BK4080","BK4231","BK4190","BK7095","BK4225","ADC.AU"],"gpt_icon":0},{"id":"2565899846","title":"先声药业(02096.HK):SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2565899846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565899846?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 20:12","pubTimestamp":1757333548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","ADC","BK1583","BK1191","BK7095","BK4231","02096","ADC.AU"],"gpt_icon":0},{"id":"2564325557","title":"招银国际:首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK4231","ADC.AU","LU1169589451.USD","PD","09887","BK4023","LU1169590202.USD","BK7095","ADC","BK4080"],"gpt_icon":0},{"id":"2561474908","title":"阿斯利康第二款ADC药物在国内获批用于乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474908","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474908?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4080","BK4585","HR","LU2462157665.USD","BK4231","BK4007","BK4568","BK4225","ADC","LU2236285917.USD","LU0889565916.HKD","LU0109394709.USD","BK4588","LU2417539215.USD","LU0320765992.SGD","BK4203","ADC.AU","LU1829250122.USD","AZN","BK7095","LU2456880835.USD"],"gpt_icon":0},{"id":"2561474158","title":"阿斯利康宣布注射用德达博妥单抗(达卓优)正式在国内获批用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474158?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZN","ADC","LU0109394709.USD","LU2417539215.USD","HR","BK7095","BK4225","LU0889565916.HKD","LU0320765992.SGD","LU1829250122.USD","BK4231","BK4080","LU2236285917.USD","BK4203","LU2462157665.USD","LU2456880835.USD","ADC.AU","BK4007","BK4568","BK4585","BK4588"],"gpt_icon":0},{"id":"2560128083","title":"研报掘金|中金:上调药明合联目标价至75港元 中期业绩胜预期且订单增长强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2560128083","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560128083?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 11:40","pubTimestamp":1755661213,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e0480a0531217974a0c2963e4454991e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1515","ADC.AU","BK4080","BK7095","LU2488822045.USD","BK1574","BK4231","SG9999014674.SGD","02268","ADC","09939","BK1161","159938","BK1141"],"gpt_icon":0},{"id":"2560151287","title":"德琪医药-B(06996.HK):ATG-022就治疗胃癌/胃食管结合部腺癌获授予突破性治疗药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2560151287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560151287?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 12:23","pubTimestamp":1755577393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK7050","BK1574","ADC.AU","BK4080","06996","BK4231","BK1191","CDE","LU1223082519.USD","ADC","LU1223083913.SGD","BK7095","BK4017","LU1223082196.USD","CDE.AU","BK1583"],"gpt_icon":0},{"id":"2556982013","title":"康宁杰瑞JSKN022新药临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2556982013","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556982013?lang=zh_cn&edition=fundamental","pubTime":"2025-08-03 20:51","pubTimestamp":1754225475,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09966","LU1223082196.USD","BK1576","BK4231","LU1169590202.USD","BK7050","BK1574","BK4080","LU1223082519.USD","PD","CDE.AU","ADC","BK1583","BK4017","BK1161","BK4023","03347","ADC.AU","IND.AU","BK1141","CDE","LU1169589451.USD","BK7095","LU1223083913.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}